• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

Recent Advances in the Application of N-(trideuteriomethyl)oxetan-3-amine (CAS: 1403767-20-3) in Chemical Biology and Pharmaceutical Research

N-(trideuteriomethyl)oxetan-3-amine (CAS: 1403767-20-3) has emerged as a pivotal compound in chemical biology and pharmaceutical research due to its unique structural properties and isotopic labeling. This deuterated derivative of oxetan-3-amine is increasingly utilized in drug discovery, particularly in the development of kinase inhibitors and proteolysis-targeting chimeras (PROTACs). Recent studies highlight its role in enhancing metabolic stability and improving pharmacokinetic profiles of lead compounds, making it a valuable tool for medicinal chemists.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the incorporation of N-(trideuteriomethyl)oxetan-3-amine into Bruton's tyrosine kinase (BTK) inhibitors, resulting in significantly improved metabolic stability in human liver microsomes. The deuterium kinetic isotope effect (DKIE) was observed to reduce oxidative metabolism at the methylene position, extending the half-life of the compound by approximately 40% compared to its non-deuterated counterpart. This finding has important implications for the design of next-generation kinase inhibitors with enhanced drug-like properties.

In the field of targeted protein degradation, researchers at a major pharmaceutical company recently reported (2024) the use of N-(trideuteriomethyl)oxetan-3-amine as a linker component in PROTAC molecules targeting estrogen receptor alpha (ERα). The deuterated linker showed improved stability against cytochrome P450-mediated oxidation while maintaining efficient target engagement and degradation activity. This advancement addresses one of the key challenges in PROTAC development - the optimization of linker chemistry to balance stability and functionality.

Analytical chemistry applications have also benefited from this compound. A novel LC-MS/MS method developed in 2023 utilizes N-(trideuteriomethyl)oxetan-3-amine as an internal standard for quantifying oxetane-containing drugs in biological matrices. The three deuterium atoms provide a consistent mass shift of +3 Da, enabling highly specific detection and accurate quantification even in complex samples. This methodology has been successfully applied to several clinical pharmacokinetic studies of investigational new drugs containing the oxetane moiety.

From a synthetic chemistry perspective, recent advances (2024) in the preparation of N-(trideuteriomethyl)oxetan-3-amine have significantly improved its accessibility for research purposes. A new catalytic deuteration method using deuterium gas and a heterogeneous palladium catalyst has achieved >98% deuteration at the methyl position with excellent yield (85-90%). This development addresses previous challenges in obtaining high-purity material at scale, facilitating broader adoption in pharmaceutical R&D.

Looking forward, the unique properties of N-(trideuteriomethyl)oxetan-3-amine position it as a key building block for several emerging therapeutic modalities. Ongoing research explores its incorporation into covalent inhibitors, where the deuterated methyl group may modulate reactivity while maintaining target engagement. Additionally, its potential in deuterated versions of approved drugs (so-called "deuterium switches") is being investigated by multiple biotech companies, with several candidates expected to enter clinical trials in 2025.

• 90225-75-5(Bis(1-methoxypropan-2-yl)amine)
• 1207175-51-6(N-Propyloxetan-3-amine)
• 104678-18-4((2-methoxyethyl)(propan-2-yl)amine)
• 1340518-89-9(N-cyclopropyloxetan-3-amine)
• 140887-45-2(1-Propanol, 3-methoxy-2-[(1-methylethyl)amino]-)
• 314771-98-7((1-methoxypropan-2-yl)(methyl)amine hydrochloride)
• 952182-03-5(N-Methyloxetan-3-amine)
• 1799412-41-1(N-methyloxetan-3-amine;hydrochloride)
• 1310732-23-0(N,3-Dimethyloxetan-3-amine)
• 1341782-83-9(N-(propan-2-yl)oxetan-3-amine)